Literature DB >> 18813868

Acid-suppressive medications and risk of bone loss and fracture in older adults.

Elaine W Yu1, Terri Blackwell, Kristine E Ensrud, Teresa A Hillier, Nancy E Lane, Eric Orwoll, Douglas C Bauer.   

Abstract

Recent studies have suggested an increased fracture risk with acid-suppressive medication use. We studied two cohorts of men and women over age 65 who were enrolled in the Osteoporotic Fractures in Men Study (MrOS) and the Study of Osteoporotic Fractures (SOF), respectively. We used dual-energy X-ray absorptiometry and assessed baseline use of proton pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs) in 5,755 men and 5,339 women. Medication use and bone mineral density (BMD) were assessed, and hip and other nonspine fractures were documented. On multivariate analysis, men using either PPIs or H2RAs had lower cross-sectional bone mass. No significant BMD differences were observed among women. However, there was an increased risk of nonspine fracture among women using PPIs (relative hazard [RH] = 1.34, 95% confidence interval [CI] 1.10-1.64). PPI use was also associated with an increased risk of nonspine fracture in men but only among those who were not taking calcium supplements (RH = 1.49, 95% CI 1.04-2.14). H2RA use was not associated with nonspine fractures, and neither H2RA use nor PPI use was associated with incident hip fractures in men or women. The use of PPIs in older women, and perhaps older men with low calcium intake, may be associated with a modestly increased risk of nonspine fracture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813868      PMCID: PMC2596870          DOI: 10.1007/s00223-008-9170-1

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  27 in total

1.  Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W S Browner; J A Cauley; H K Genant; S R Mascioli; J C Scott; D G Seeley; P Steiger
Journal:  JAMA       Date:  1990-02-02       Impact factor: 56.272

2.  The Physical Activity Scale for the Elderly (PASE): development and evaluation.

Authors:  R A Washburn; K W Smith; A M Jette; C A Janney
Journal:  J Clin Epidemiol       Date:  1993-02       Impact factor: 6.437

3.  Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro.

Authors:  J Tuukkanen; H K Väänänen
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

4.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

Authors:  Robert J F Laheij; Miriam C J M Sturkenboom; Robert-Jan Hassing; Jeanne Dieleman; Bruno H C Stricker; Jan B M J Jansen
Journal:  JAMA       Date:  2004-10-27       Impact factor: 56.272

5.  Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group.

Authors:  K E Ensrud; T Duong; J A Cauley; R P Heaney; R L Wolf; E Harris; S R Cummings
Journal:  Ann Intern Med       Date:  2000-03-07       Impact factor: 25.391

6.  Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.

Authors:  G L Cui; U Syversen; C M Zhao; D Chen; H L Waldum
Journal:  Scand J Gastroenterol       Date:  2001-10       Impact factor: 2.423

7.  Risk factors for hip fractures in men: a preliminary study.

Authors:  J A Grisso; G Y Chiu; G Maislin; W C Steinmann; J Portale
Journal:  J Bone Miner Res       Date:  1991-08       Impact factor: 6.741

8.  Calcium absorption and achlorhydria.

Authors:  R R Recker
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

9.  Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion.

Authors:  Giorgio Graziani; Salvatore Badalamenti; Giovanna Como; Maurizio Gallieni; Silvia Finazzi; Claudio Angelini; Diego Brancaccio; Claudio Ponticelli
Journal:  Nephron       Date:  2002-07       Impact factor: 2.847

10.  Lumbar spine listhesis in older African American women.

Authors:  Molly T Vogt; David A Rubin; Lisa Palermo; Lisa Christianson; James D Kang; Michael C Nevitt; Jane A Cauley
Journal:  Spine J       Date:  2003 Jul-Aug       Impact factor: 4.166

View more
  74 in total

1.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Authors:  Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen
Journal:  Arch Intern Med       Date:  2010-05-10

Review 2.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

3.  The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

4.  Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

Authors:  Daniel H Solomon; Susan J Diem; Kristine Ruppert; Yin Juan Lian; Chih-Chin Liu; Alyssa Wohlfart; Gail A Greendale; Joel S Finkelstein
Journal:  J Bone Miner Res       Date:  2015-02       Impact factor: 6.741

5.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

6.  Treatment of postmenopausal osteoporosis in a patient with celiac disease.

Authors:  JoAnn V Pinkerton; Alan C Dalkin; Sheila E Crowe; Barbara B Wilson; Edward B Stelow
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

7.  Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.

Authors:  Paul Moayyedi; Yuhong Yuan; Grigorios Leontiadis
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

8.  Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.

Authors:  T N Poly; M M Islam; H-C Yang; C C Wu; Y-C J Li
Journal:  Osteoporos Int       Date:  2018-12-12       Impact factor: 4.507

9.  Another bad break for proton-pump inhibitors?

Authors:  Laura E Targownik
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

10.  Bone density in proton pump inhibitors users: a prospective study.

Authors:  Kamil Ozdil; Resul Kahraman; Abdurrahman Sahin; Turan Calhan; Erdem H Gozden; Umit Akyuz; Burak Erer; Mehmet H Sokmen
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.